Atlas Trials

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Clinical trial NCT03937635 · RECRUITING

Trial details

NCT number
NCT03937635
Sponsor
ECOG-ACRIN Cancer Research Group
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Smoldering Plasma Cell Myeloma
Start date
2019-09-16
Primary completion
2029-12-31
Enrollment
288

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.